ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1388

Characteristics and Symptom Severity in 21,101 Patients Reporting Systemic Lupus Erythematous in the Patientslikeme Online Health Community

Elisabeth Nyman1, Edward R. Hammond2, Timothy Vaughan3, Barnabas Desta2, Xia Wang2, Volkan Barut4 and Cathy Emmas5, 1Advanced Analytics Centre, AstraZeneca, Gothenburg, Sweden, 2AstraZeneca, Gaithersburg, MD, 3PatientsLikeMe, Boston, MA, 4Global Medical Affairs, AstraZeneca, Cambridge, United Kingdom, 5Patient Centricity, AstraZeneca, Cambridge, United Kingdom

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: online patient engagement and patient-reported outcome measures, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Patient Outcomes, Preferences, and Attitudes Poster I: Patient-Reported Outcomes

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Online health communities and research networks such as PatientsLikeMe (PLM) provide important insight into understanding chronic diseases, including systemic lupus erythematous (SLE). We aimed to characterize PLM SLE population by their initial reported patient characteristics.

Methods: Retrospective observational study in PLM online health network. Patients were included in the study if they had registered with PLM between 2011-2017, were aged over 18 years at the time of registration, and reported both SLE and treatment with one or more SLE medications (anti-malarials, immunosuppressive, corticosteroids, calcineurin inhibitors and biologics). Information reported within 30 days of registration was used to assess eligibility and in descriptive analysis to characterize the demographic and clinical characteristics, co-morbidities, treatment of patients and the severity of symptoms they reported, both general (included in symptom panel for all PLM patients) and additional SLE symptoms.

Results: 21,101 patients met the inclusion criteria and were identified as patients with SLE. The median age at registration was 46 years (IQR 38-53), the majority were female (96.8%, N=21 050), and 94.8% (18,491) of the 19,502 patients who reported country were US residents. The 17,994 patients who recorded race were predominately Caucasian (67.8%) and African-American (22.4%). In the 6 489 patients who reported when they had first experienced SLE symptoms the median age of onset was 30 years (IQR 21-39) and age at first diagnosis was 36 years (IQR 27-44) (N=6 936). The most commonly reported comorbidities were fibromyalgia 7.9%, discoid lupus 6.8%, lupus nephritis 6.3%, rheumatoid arthritis 4.8%, subacute cutaneous lupus 4.7%, Sjogren’s Syndrome 3.9%, CNS lupus 3.9%, and lupus pneumonitis 3.1%.  At registration patients reported having tried an average of 2.2 SLE medications, most commonly; anti-malarials 83.8%, corticosteroids 78.8%, immunosuppressive 32.3%, and biologic treatment 9.4%. Around 31% of patients (N=6,448) entered any symptom report at registration, and >80% of the patients who reported them rated the severity of fatigue, pain, and joint pain as moderate or severe (Table 1).

Conclusion: The age, gender and race of SLE patients in the PatientsLikeMe community are broadly consistent with what is known about the US SLE population. The PLM SLE population provides a unique source of real world information on the patient experience of symptoms of SLE outside the clinical environment that can be utilized to improve understanding of SLE.

 


Disclosure: E. Nyman, AstraZeneca, 3; E. R. Hammond, AstraZeneca, 1, 3; T. Vaughan, PatientsLikeMe, 3; B. Desta, AstraZeneca, 1, 3; X. Wang, AstraZeneca, 1, 3; V. Barut, AstraZeneca, 1, 3; C. Emmas, AstraZeneca, 1, 3.

To cite this abstract in AMA style:

Nyman E, Hammond ER, Vaughan T, Desta B, Wang X, Barut V, Emmas C. Characteristics and Symptom Severity in 21,101 Patients Reporting Systemic Lupus Erythematous in the Patientslikeme Online Health Community [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/characteristics-and-symptom-severity-in-21101-patients-reporting-systemic-lupus-erythematous-in-the-patientslikeme-online-health-community/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characteristics-and-symptom-severity-in-21101-patients-reporting-systemic-lupus-erythematous-in-the-patientslikeme-online-health-community/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology